Mechanisms of hepatic fibrogenesis induced by hepatitis C virus (HCV), one of the leading causes of liver fibrosis, are not fully understood. We studied transcriptional up-regulation of transforming growth factor b (TGF-b), especially TGF-b2, which is mediated by activation of liver-enriched transcription factor cAMP-responsive element-binding protein, hepatocyte specific (CREBH) triggered by HCV infection and its functional significance for induction of profibrogenic phenotypes by interaction of HCV-infected cells with hepatic stellate cells (HSCs). Compared to TGF-b1, expression of TGF-b2 mRNA was induced faster and to a higher level upon HCV infection. Serum TGF-b2 levels in hepatitis C patients were higher compared to those in healthy individuals and were positively correlated with hepatic fibrosis stages F0-F2. TGF-b2 promoter activity was decreased and increased, respectively, by silencing and overexpression of CREBH. CREBH recognition sites were identified in the TGF-b2 promoter. CREBH binding to the promoter and its increase in cells expressing HCV Core-NS2 were shown by gel mobility shift and chromatin immunoprecipitation, respectively. The active form of CREBH was detectable in HCV-infected chimeric mice with human livers and cells expressing HCV proteins. Involvement of CREBH in HCV-induced fibrogenic response was further demonstrated in the CREBH null-mutant mouse model. Fibrogenic phenotypes were assessed using co-cultures of HCV-infected cells and HSCs. Expressions of fibrogenic factors and TGF-b1 increasing in the co-cultures was prevented by TGF-b2-or CREBH silencing. Conclusion: CREBH was identified as a key positive regulator of TGF-b2 transcription in HCV-infected cells. TGF-b2 released from infected cells potentially contributes to cross-induction of TGF-b in an autocrine manner through its own signaling pathway, leading to an increase in fibrogenic responses in adjacent HSCs.
C hronic infection with hepatitis C virus (HCV)
often results in the development of hepatic fibrosis (HF), which is characterized by the progressive replacement of functional liver tissue with cross-linked collagen-rich extracellular matrix (ECM), and perturbs the functions of the liver especially in the end stage of cirrhosis. Furthermore, hepatocellular carcinoma (HCC) develops frequently in patients with the advanced HF. Although research directed toward understanding liver fibrogenesis has made some progress, the molecular mechanisms by which HCV infection modulates this process still remain poorly defined.
Generally, progression of liver fibrosis (LF) is promoted by activated hepatic stellate cells (HSCs), which secrete substantial amounts of ECM upon activation by several cytokines. Transforming growth factor beta (TGF-b) is one of the best-characterized cytokines and affects cell growth, cell death, morphogenesis, and induction of a fibrogenic response. (1) It is known that, in liver tissues, TGF-b is produced and secreted not only by the nonparenchymal cells, but also by hepatocytes. There are three mammalian TGF-b isoforms; TGF-b1, TGF-b2, and TGF-b3. Regarding its association with LF, elevated expression of TGF-b1 and -b2 was observed in liver tissues of patients with chronic HCV infection. (2) TGF-b3 has been reported to have an antifibrotic effect in the liver. (3) Several studies of mechanisms by which HCV infection induces TGF-b expression or activates the TGF-b pathway have been carried out. For example, expression of HCV Core or E2 contributes to an increase in expression and secretion of TGF-b, and increased levels of reactive oxygen species (ROS) caused by HCV infection are involved in TGF-b production. (4, 5) Another study has shown that the HCV nonstructural (NS) 3 potentially mimics TGF-b2 and functions through binding to TGF-b receptor I. (6) Here, we found that cAMP responsive elementbinding protein, hepatocyte specific (CREBH) functions as a key factor for transcriptional regulation of TGF-b2 in hepatic cells. Although recent studies have shown that CREBH regulates hepatic gluconeogenesis, triglyceride metabolism, and iron metabolism in the liver, (7, 8) its role in liver fibrogenesis is totally unknown. Based on the findings obtained, we propose that TGF-b2 released from HCV-infected cells contributes to cross-induction of TGF-b in these cells in an autocrine manner through its own signaling pathway, finally leading to an increase in fibrogenic responses in HSC adjacent to the infected cells through paracrine TGF-b signaling.
Materials and Methods

MATERIALS
Cell cultures, reagents, cell isolation, adenovirus vectors, plasmids, and their cloning strategies are described in the Materials and Methods of the Supporting Information.
VIRUS INFECTIONS AND DNA TRANSFECTION
J6/JFH-1-derived HCV was prepared as described. (9) Na€ ıve Huh7.5.1 cells were infected with HCV J6/JFH-1 at various multiplicities of infection (MOIs) for 4 hours. Lipofectamine LTX (Thermo Fisher Scientific, Waltham, MA) or TransIT-X2 (Takara Bio, Tokyo, Japan) were used for DNA transfection.
MOUSE MODELS
Chimeric mice with a humanized liver were purchased from Phoenix Bio (Hiroshima, Japan). (10) The replacement index of human hepatocytes that had repopulated the host mouse livers used in this study was predicted to be above 70%. The inoculum used was HCV genotype 1b that was obtained from the serum of an HCV-infected individual. At 35 days postinfection (dpi), mice were sacrificed and liver tissues were collected.
Thirty-week-old male C57/BL6J (WT) mice were obtained from SLC Japan (Hamamatsu, Japan), and CREBH null-mutant, Creb3l3 tm1.1Sad
) mice were purchased from Jackson Laboratory. (11) For adenoviral infection, 30-week-old male mice were infected with recombinant adenovirus expressing Cre recombinase (12) and either of green fluorescence protein (GFP) or HCV Core-NS2 (see Supporting Materials and Methods) at 1.0 3 10 9 pfu per body, followed by collecting liver samples 4 dpi. Animal husbandry procedures and experiments using WT and Creb3l3 2/2 mice were performed in accord with the Regulation of Animal Experiments of the Hamamatsu University School of Medicine (Hamamatsu, Japan) and were approved by the Animal Experiment Committee of the university.
GENE KNOCKOUT
CREBH-knockout cells were produced using the CRISPR-Cas9 system using pX330-U6-Chimeric_ BB-CBh-hSpCas9 that was a gift from Feng Zhang (Addgene plasmid #42230). At 28 days posttransfection (dpt) with a plasmid inserting the target sequence of CREBH, single cell clones were selected and mutations within the CREBH gene were confirmed by DNA sequencing.
METHODS OF IN VITRO ASSAYS, STATISTICAL ANALYSIS
The following assays are described in the Supporting Information: gene silencing; RNA extraction and RT-PCR; luciferase reporter assay; indirect immunofluorescence analysis; western blotting and immunoprecipitation; enzyme-linked immunosorbent assay (ELISA); scratch-wound assay, chromatin immunoprecipitation (ChIP) assay; gel-shift assay; and statistical analysis.
Results
INDUCTION OF TGF-b, IN PARTICULAR TGF-b2 EXPRESSION, BY HCV INFECTION
We first evaluated expression of both TGF-b1-and TGF-b2 mRNAs after HCV infection of Huh7.5.1 cells using qRT-PCR. Whereas expression of both TGF-b mRNAs was increased by HCV infection in a dose-dependent manner, higher TGF-b2 expression was induced compared to TGF-b1 expression after viral infection (Fig. 1A) . TGF-b2 expression was more rapidly induced by HCV infection compared to TGFb1 expression in the time-course analysis. An increase in TGF-b2 level was detectable at 2 dpi and its level reached to >10-fold higher than control cells at 4 dpi (Fig. 1B) . Induced expression of TGF-b2 after HCV infection was completely abolished by pretreatment with anti-CD81 antibody (Fig. 1C) . These data demonstrated that HCV infection results in the induction of TGF-b, in particular to TGF-b2 expression. To determine whether serum levels of TGF-b2 in hepatitis C patients were correlated with the fibrosis stages in their livers, patients' peripheral sera were collected with liver tissues at various fibrosis stages, as judged by the METAVIR Score, and their serum TGF-b2 levels were measured using an ELISA (Fig. 2) . The background data of these patients are shown in Supporting  Table S2 . Overall, TGF-b2 levels in hepatitis C patients were higher compared to the level in healthy controls. There was a significant difference between TGF-b2 levels among the groups with different fibrosis stages (P <0.0001, using one-way analysis of variance [ANOVA] To further demonstrate correlation between HCV infection and profibrotic gene expression in the clinical setting, mRNA levels of TGF-b2, TGF-b1, and a-SMA in livers of chronic hepatitis C (CHC) patients' (serum HCV-RNA levels; 10 6 to 10 7 copies/mL) before anti-HCV therapy were compared with those achieving sustained viral response attributed to successful therapy. As expected, although decreasing degrees varied among patients tested, hepatic levels of TGFb2, TGF-b1, and a-SMA mRNAs were reduced in response to anti-HCV therapy (Supporting Fig. S1 ). These studies using clinical samples were approved by the Ethics Committee of Hamamatsu University School of Medicine.
INVOLVEMENT OF CREBH IN UP-REGULATION OF THE TGF-b2 PROMOTER ACTIVITY INDUCED BY HCV
To understand how HCV infection leads to an increase in TGF-b2 mRNA expression, a series of luciferase reporter plasmids harboring the promoter sequence required for TGF-b2 transcription or its mutants (Fig. 3A) were generated. Luciferase activities in HuH-7 or HepG2 cells transfected with the 
FIG. 2.
Quantification of TGF-b2 in patients' sera. Peripheral blood sera were collected from CHC patients with various fibrosis stages in their liver tissues, as judged by METAVIR scores. Sera from healthy individuals were used as a control. Serum TGF-b2 levels were determined using an ELISA. Mean values of each group are indicated as horizontal lines. There were significant differences in TGF-b2 levels between groups as analyzed using one-way ANOVA (P < 0.0001). Tukey's multiple comparison tests were done as a post-hoc test. Statistical significances compared to the healthy group were: **P < 0.01 for the F3; ****P < 0.0001 for the F2 and F1 groups.
reporter plasmids with or without HCV proteinexpression plasmids were determined. It has been reported that HCV Core contributes to positive regulation of TGF-b2 expression.
(4) TGF-b2 promoter activity was marginally or moderately increased by expression of Core alone ( . A significant induction of TGF-b2 mRNA expression by Core-NS2 was confirmed in both HuH-7 (P < 0.01) and HepG2 (P < 0.001) cells (Fig. 3C ). It has been reported that the promoter regions at nucleotides (nt) -74/-67 and -50/-45 (relative to the transcription start site), (13) which are a cAMP response element-like (CRE-L) sequence and an E-box motif respectively, are important for transcriptional regulation of the TGF-b2 gene. (14) Consistent with these findings, reporter assays of the TGF-b2 promoter with 5 0 end-deletions demonstrated that whereas a deletion extending to nt -100 (pGL-b2pr-100) had no influence on promoter activity, further deletion up to nt -64 (pGL-b2pr-64) resulted in a marked decrease in promoter activity (Fig. 3D , left). Our database search indicated that the nt -49/-43 sequence (ACGTGGT) in the TGF-b2 promoter contained the consensus sequence of the response element for the liver-enriched transcriptional factor, CREBH (CREBHRE). (15, 16) Given that CREBH is known to bind the CRE consensus sequence (TGACGTCA), (7, 17) it was possible that it might also recognize the CRE-L sequence (GCACGTCA). We therefore examined whether CREBH is involved in TGF-b2 transcriptional regulation. In the promoter assay, substitution mutations either within CRE-L (CRELm) or CREBHRE (CREBHREm) led to not only a marked decrease in promoter activity, but also to a reduced effect of Core-NS2 on promoter activity. The promoter activity from constructs with double mutations within CRE-L and CREBHRE (Dm) was comparable to that at the background level. No significant influence on promoter activity was observed by substitutions at the potential activator protein-1 (AP1)-binding site, which was used as a negative control ( Next, to assess recruitment of transcription factors to the TGF-b2 promoter in cells, ChIP assays with or without Core-NS2 expression were performed (Fig.  3E ). The amplified DNA fragments covering the CRE-L/CREBRE region were detected after immunoprecipitation with anti-CREBH or anti-ATF (activating transcription factor) 2 antibody. DNA levels were clearly higher in Core-NS2-expressing cells. To further determine interaction of CREBH with the TGF-b2 promoter, gel-shift assays were performed using end-labeled oligonucleotides corresponding to nt -86/-56 (b2-1) and -61/-32 (b2-2) of the promoter that contain CRE-L and CREBHRE sites, respectively (Fig. 3F) . When the synthesized CREBH-N, ATF2, and ATF6 proteins were mixed with each probe, CREBH-N bound to both b2-1 and b2-2, but not to their substitution mutants (b2-1m and b2-2m). Excess amounts of unlabeled homologous probes (b2-1, b2-2) competed with its binding. ATF2 bound to b2-1, but not to b2-2 (Supporting Fig. S4 ).
These findings suggest that CREBH contributes to up-regulation of TGF-b2 promoter activity through its binding to the sequences corresponding to CRE-L and CREBHRE. Core-NS2 expression may induce recruitment of CREBH to the TGF-b2 promoter in cells. , results represent the means with SD from three independent transfectants. (E) At 2 dpt with the Core-NS2 expressing vector or EV, cells were harvested and nuclear fractions were used for ChIP assays. Protein-DNA complexes were immunoprecipitated with antibody against either the transcription factors, ATF2, phospho-CREB (pCREB), or CREBH, or with control rabbit IgG. Precipitates were analyzed for qPCR using the two different pairs of primers; ChIP1 and ChIP2. (F) Aliquots of in vitro synthesized CREBH-N, ATF6, ATF2, or HCV Core were mixed with a probe containing the CRE-L (b2-1) or CREBHRE (b2-2) region for gel-shift assays. Probes containing the consensus binding sequences of CRE and ATF6 were used as positive controls (upper). Competition assays were performed with excess amounts of unlabeled homologous probes (lower left and middle). Probes named b2-1m and b2-2m had a mutation in the sequence of CRE-L and CREBHRE, respectively (lower right). *P<0.05; **P<0.01; ***P < 0.001 (P values are shown in parentheses if they show significance of decrease). Abbreviations: GAPDH, glyceraldehyde 3-phosphate dehydrogenase; IgG, immunoglobulin.
HCV-INDUCED CREBH ACTIVATION PLAYS A KEY ROLE IN ELEVATED EXPRESSION NOT ONLY OF TGF-b2, BUT ALSO OF TGF-b1
It is known that upon endoplasmic reticulum (ER) stress the 75-kDa precursor form of CREBH (CREBH-F) is proteolytically processed into its N-terminal 50-kDa active form (CREBH-N), which then enters the nucleus to act as a transcription factor. Transcriptome analysis indicated that several genes that are known to be induced by ER stress, such as insulin-like growth factor binding protein-1, C/EBP homologous protein, and growth arrest and DNA damage-inducible protein 34, were upregulated upon HCV infection in cells (Supporting Table  S3 ). In addition, mRNA expression of CREBH was moderately induced by HCV infection (Supporting Fig.  S5 ). We therefore analyzed proteolytic processing of CREBH in cells by western blotting. The amount of the activated CREBH-N form was markedly higher in Core-NS2-expressing cells than in cells without Core-NS2 (Fig. 4A) . Furthermore, higher expression of endogenous CREBH-N was detected in livers of humanized liver chimeric mice infected with HCV than that in uninfected mice (Fig. 4B) .
Next, to ask whether CREBH is responsible for the increased expression of TGF-b2 that is triggered by HCV infection, we used a mutated form of CREBH in which its N-terminal region that is important for transcriptional activation (18) is deleted. This mutant is known to function as a dominant negative (DN) mutant. The increased level of the TGF-b2 promoter activity that is induced either by HCV infection or by Core-NS2 expression was markedly reduced by coexpression of DN-CREBH-N (Fig. 4C) . HCVinduced promoter activity was also inhibited by small interfering RNA (siRNA)-mediated CREBH knockdown (Fig. 4D) . Additionally, in contrast to the high level of TGF-b2 mRNA in parental cells induced upon HCV infection, there was a much smaller increase in the HCV-infected CREBH-knockout cells (Fig. 4E, upper left) . Comparable sensitivity to HCV infection of the CREBH-knockout and parental cells was confirmed by western blotting (Fig. 4E, lower) . Given that TGF-b expression is positively regulated through cross-induction by TGF-b isoforms, (19) we confirmed that, when Huh7.5.1 cells were cultured in the presence of TGF-b1 or -b2 for 2 days, expression levels of both TGF-b isoforms markedly increased (Supporting Fig. S6 ). In a TGF-b1 or -b2 reporter assay, CREBH-N expression resulted in a marked increase in TGF-b2 promoter activity, but only a little influence on the TGF-b1 promoter activity (Supporting Fig. S7A ). TGF-b2 knockdown led to diminishing such an influence of CREBH-N on the TGF-b1 promoter (Supporting Fig. S7B) . No increase in TGFb1 expression was observed following HCV infection of CREBH-knockout cells (Fig. 4E, upper right) .
To address the role of CREBH on profibrogenic response in livers induced by HCV protein expression in the animal model, C57/BL6J (wild-type; WT) and CREBH-knockout (Cleb3l3 -/-) mice were intravenously infected with adenovirus vectors that express HCV Core-NS2 polyprotein or GFP. Expression of HCV proteins led to a significant increase in mRNAs of TGF-b2, TGF-b1, and alpha-smooth muscle actin (a-SMA) in livers of WT mice (Fig. 5) . In contrast, no increase in mRNA expresion of these genes was observed in livers of Cleb3l3 -/-mice, indicating involvement of CREBH in up-regulation of profibrogenic response induced by HCV protein expression in liver tissues.
Collectively, these findings strongly suggest that CREBH primarily plays a key role in activation of the TGF-b2 promoter that is induced by HCV infection, and that it eventually contributes to expression of TGF-b1 as well as of TGF-b2 in the infected cells.
EXPRESSION AND SECRETION OF TGF-b FROM HCV-INFECTED CELLS MEDIATES PROFIBROGENIC EFFECTS ON HSCs
We developed a co-culture system of TWNT4, human HSC-derived cells, with HCV-infected Huh7.5.1 cells to examine the profibrogenic effects of TGF-b2 released from infected cells on HSCs. TWNT4 cells, which are immortalized HSCs with some activated phenotype (20) and were found to retain the capability to be further activated by TGF-b treatment. Exposure of these cells to TGF-b1 or -b2 led to increased expression of type I collagen (COL1A1) in a dose-dependent manner (Supporting Fig. S8A,B) . Such collagen induction by TGF-b did not occur following pretreatment with a TGF-b receptor inhibitor (Supporting Fig. S8C ). After overnight incubation of a mixture of emGFP-expressing TWNT4 cells and viral-or mock-infected Huh7.5.1 cells (cell number ratio of 1:5) in a collagen-coated dish, cells were grown as monolayers, but the two types of cells were compartmentalized; colony-like forms of Huh7.5.1 cells were apparently surrounded by TWNT4 cell populations (Supporting Fig. S9A ). Immunofluorescence analysis of Core expression showed little or no virus transmission to TWNT4 cells after at least 3 days of co-culture with infected Huh7.5.1 cells (Supporting Fig. S9B ). Three-day co-culture of TWNT4 and HCV-infected Huh7.5.1 cells showed significantly higher expression not only of TGFb2 (P < 0.001), but of COL1A1 (P < 0.05) and aSMA (P < 0.05) mRNA than that with mock-infected cells (Fig. 6A) . In the TWNT4 monoculture, in which twice the number of TWNT4 cells were used compared to the co-culture settings, expression of these profibrogenic factors was similar in the presence and absence of HCV, suggesting that a fibrogenic response was not induced in TWNT4 cells by virus attachment to the cell surface (Fig.  6A) . A significant increase in COL1A1 protein level in the co-culture of TWNT4 cells with infected Huh7.5. HCV-infected cells were co-transfected with pGL-b2pr and either the DN-CREBH-N-expressing vector or EV at 1 dpi. Two days later, luciferase activities in cells were determined (upper). Cells were co-transfected with pGL-b2pr and either the DN-CREBH-Nexpressing vector or EV together with or without Core-NS2-expressing vector. At 2 dpt, luciferase activities in cells were determined (lower). (D) At 1 day after introduction of CREBH siRNAs (siCREBH) or its negative control (siNC), cells were co-transfected with pGL-b2pr and Core-NS2-expressing vector or EV. At 2 dpt, luciferase activities in cells were determined. (E) CREBHknockout (CREBH-KO) and parental Huh7.5.1 cells were cultured with (1) or without (-) HCV infection for 3 days, following which mRNA expression of TGF-b2 (left) and -b1 (right) was quantified. For (C)-(E), results represent the means with SD from three independent experiments. *P<0.05; **P<0.01; ***P <0.001. Abbreviations: EV, empty vector; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; WB, western blotting.
immunofluorescence microscopic images (Fig. 6B) . No immunofluorescent signal for COL1A1 was detectable in Huh7.5.1 monoculture either with or without HCV infection (Supporting Fig. S10 ). Moreover, a scratch-wound assay of cell migration showed that the migration rate of TWNT4 cells was significantly higher (P < 0.01) in the presence of culture medium from HCV-infected cells than that from noninfected cells (Fig. 6C) .
To further study the effect of loss or gain of function of TGF-b2 on the profibrogenic effect induced by HCV infection in the co-culture system, Huh7.5.1 cells were transfected with a plasmid encoding a shorthairpin RNA (shRNA) targeted to TGF-b2 (shTGFb2). The susceptibility to HCV in knockdown cells was comparable to that of control cells carrying an empty vector (Supporting Fig. S11 ). The increased mRNA expression of COL1A1 and TGF-b1 as well as activation of Smad3 signaling that were observed in the co-culture of TWNT4 cells and infected control Huh7.5.1 cells was greatly impaired in the co-culture of TWNT4 cells with infected TGF-b2-knockdown Huh7.5.1 cells (Fig. 6D) . A similar effect on COL1A1 expression by TGF-b2 knockdown was observed (Fig. 6E) . Introduction of a plasmid expressing shRNA-resistant TGF-b2 (TGFb2-sh r ) into knockdown cells before infection reduced the inhibitory effect of TGF-b2 knockdown on the profibrogenic effects induced in the TWNT4 co-culture with HCV-infected cells. Finally, to assess the role of CREBH in the HCV-induced profibrogenic effect, Huh7.5.1 cells in which either CREBH siRNA or nontargeting siRNA was transfected were used. In TWNT4 co-culture with these cells, the increased expression of COL1A1 mRNA induced by HCV infection was prevented by siRNA-mediated knockdown of CREBH (Fig. 6F, upper) . Similar results were obtained when CREBH-knockout Huh7.5.1 cells were infected with HCV and co-cultured with TWNT4 cells (Fig. 6F, lower) .
Overall, our findings demonstrate that elevated expression of TGF-b2 through CREBH activation triggered by HCV infection plays a critical role in the induction of the profibrogenic phenotypes of HSC adjacent to the infected cells.
Discussion
Although activation of TGF-b signaling is critical for fibrogenesis in livers, a complete understanding of the mechanistic roles of HCV infection in TGF-b expression and induction of HF remains to be defined. In this study, we showed that CREBH activation induced by HCV infection plays a key role in upregulation of TGF-b2 expression and promotion of profibrogenic responses in HSCs adjacent to infected cells. CREBH is an ER-bound transcription factor and is activated in response to stress stimuli such as ER stress and metabolic stress. (21, 22) Among the HCV proteins tested, expression of the Core-NS2 polyprotein, which can induce considerable ER stress, (23) exhibited the highest induction of TGF-b2 promoter mice were infected with the adenovirus expressing Cre recombinase, together with the adenovirus expressing either GFP or HCV Core-NS2. At 4 dpi, liver tissues were collected and total RNA was extracted, followed by determining TGF-b2, TGF-b1, and a-SMA mRNAs by qRT-PCR. Results represent the means with SD (4 mice in the WT group, 3 mice in the Creb3l3 2/2 group). Mean values of each control GFP group were set to 1.0. Expression of HCV RNA in mouse livers was detected by RT-PCR. *P<0.05; **P<0.01. Abbreviation: GAPDH, glyceraldehyde 3-phosphate dehydrogenase. activity ( Fig. 3B and Supporting Fig. S2 ). ER stress is emerging as a significant factor in fibrotic disorders, although the mechanisms are not well understood. To our knowledge, this is the first demonstration of the involvement of activation of an ER-resident transcription factor induced by viral infection in profibrogenic responses.
CREBH, a member of the CREB/ATF6 family, is known to regulate the gene expression related to glucose and lipid metabolism. (7, 24, 25) However, no study of the role of CREBH in fibrosis or in expression of fibrogenic-related genes has been reported to date. Regarding the regulation of TGF-b2 gene expression, it has been reported that the transcription factors, specificity protein 1, ATF1, ATF2, cAMP-response-element)-binding protein (CREB), and upstream stimulatory factors, are involved in TGF-b2 promoter activity. (13, 14, 26) One study showed that HCV Core induces phosphorylation of ATF2 and c-Jun, which may contribute to TGF-b2 expression. (4) However, the role of their phosphorylation in HCV-induced TGF-b2 expression has not been elucidated. We found that ethyl 2,7-dioxo-2,7-dihydro-3H-naphtho[1,2,3-de]quinoline-1-carboxylate (NQDI-1), apoptosis signalregulating kinase 1 inhibitor, did not inhibit HCVinduced TGF-b2 promoter activity (Supporting Fig.  S12 ). Here, we demonstrated a critical role for CREBH activation in TGF-b2 expression induced by HCV infection. The promoter assay showed that TGF-b2 promoter activity was reduced to the background level by dual substitution mutations within CRE-L and CREBHRE (Dm in Fig. 3D ). The gel-shift and chromatin immunoprecipitation analyses indicated that CREBH physically binds to the regions within the TGF-b2 promoter containing CRE-L and CREBHRE (Fig. 3E,F) . HCV infection or Core-NS2 expression led to promotion of precursor processing of CREBH to its active form, CREBH-N (Fig. 4A,B) . Whereas overexpression of CREBH increased TGF-b2 promoter activity, expression of DN-CREBH-N or knockdown or knockout of CREBH prevented HCV induction of TGF-b2 expression (Fig. 4C-E and Supporting Fig. S3 ). CREBH knockout resulted in significant repression of both basal and Core-NS2 induced TGF-b2 promoter activity in the presence or absence of NQDI-1 (Supporting Fig. S12 ). It is thus likely that CREBH activation, rather than the ROS-mediated signaling pathway, is more critical for HCV-induced upregulation of TGF-b2.
It has been reported that HCV infection is associated with a significant increase in TGF-b expression in both serum and liver. (2, 27, 28) This study confirms that serum TGF-b2 levels were higher in patients with chronic HCV infection than in healthy controls and demonstrates a positive correlation between serum TGF-b2 levels and the stages of HF in HCV patients with early HF (F0-F2; Fig. 2 and Supporting Table  S2 ). It may thus be possible that serum TGF-b2 value has potential to function as a diagnostic and prognostic marker for LF and cirrhosis. Serum TGF-b2 levels were somewhat lower in patients with fibrosis stages F3 and F4, compared with those in patients with stage F2, presumably because the numbers of platelets that produce TGF-b and are its major storage tissue were decreased according to a reduction of liver function in late stages of fibrosis. (29) In previous reports that used cell-culture systems, the effect of HCV infection or replication on TGF-b1 (30, 31) and -b2 (4) was investigated separately. Here, we evaluated expression of both TGF-b1 and -b2 in HCVinfected-and viral-protein-expressing cells. Upon HCV infection, an increase in TGF-b2, but not TGFb1 expression, was immediately observed, and the HCV infection-induced increase in TGF-b2 expression over time was much higher compared with that in TGF-b1 (Fig. 1B) . Overexpression of CREBH-N markedly induced TGF-b2 promoter activity, but resulted in only moderate induction of TGF-b1 promoter activity (Supporting Fig. S7A ). No induction of TGF-b1 promoter activity by CREBH-N was observed in TGF-b2 knockdown cells (Supporting Fig. S7B ). HCV-induced increase in expression of TGF-b1 was suppressed by TGF-b2 knockdown (Fig. 6D) or by CREBH knockout (Fig. 6F) . It is known that total TGF-b expression or EV was introduced into knockdown cells. Two days later, cells were mixed with TWNT4 and co-cultured for 4 days. mRNA expression of COL1A1 and TGF-b1/2 were quantified. Smad3 were immunoprecipitated with an anti-Smad3 antibody, followed by western blotting to detect whole (Smad3) and phosphorylated form of (p-Smad3) Smad. Relative protein levels of p-Smad3 normalized to Smad3 were calculated by band intensities. (E) At 1 dpi, Huh7.5.1 cells with or without TGF-b2 knockdown and with or without HCV infection were mixed with TWNT4 cells. After 3 days, COL1A1 and GAPDH were analyzed by western blotting. (F) One day after introducing CREBH siRNA (siCREBH) or its negative control (siNC), Huh7.5.1 cells were infected with/without HCV and co-cultured with TWNT4 cells for 3 days. COL1A1 mRNA expression was quantified (upper). Huh7.5.1 cells with or without CREBH-KO (knockout) were infected with/without HCV. At 1 dpi, cells were co-cultured with TWNT4 for 3 days (lower). *P<0.05; **P<0.01; ***P <0.001. Abbreviations: EV, empty vector; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; shRNA, short hairpin RNA; Smad, small mothers of decapentaplegic.
is regulated by an autocrine signaling loop that is triggered by binding of each TGF-b isoform to the cognate receptor complex. We confirmed a marked increase in expression of both TGF-b1 and -b2 by adding either TGF-b1 or -b2 to Huh7.5.1 cells (Supporting Fig. S6 ). Generally, TGF-b1 levels in sera and tissues are higher than TGF-b2 level.
Based on our findings, together with what is known about TGF-b, it is likely that the increase in TGF-b expression in HCV-infected cells is initiated through up-regulation of TGF-b2 promoter activity by the infection-dependent activation of CREBH, which leads to cross-induction of TGF-b1 through TGFb2-dependent autocrine pathway.
Molecular mechanisms of hepatic fibrogenesis have been studied using several culture models, in which culture supernatants of hepatocyte-derived cells with or without stimuli including HCV protein expression were transferred to HSC culture (5, 32, 33) or in which both types of cells were co-cultured under direct contact or noncontact conditions. (34, 35) In HCV-mediated fibrogenesis, up-regulation of fibrogenic factors was reported in a co-culture of HSCs with HCV Coreexpressing cells, (34) and TGF-b1 secreted from the E2-expressing cells activated the HSCs. (5) HCV/ human immunodeficiency virus co-exposure in hepatocytes and HSC revealed cooperative transcriptional activation of profibrotic pathways. (33) However, the impact of knockdown or knockout of the key molecules that were identified in their study on fibrogenic responses were not determined in the co-culture setting. In the present study, we demonstrated that, compared to HCV-infected-Huh7.5.1 cells or TWNT4 cells alone, contact co-culture between infected cells and TWNT4 cells resulted in significantly higher expression of COL1A1 (P < 0.05) and a-SMA (P < 0.05). Interestingly, induced expression of COL1A1 by HCV infection in the co-culture system was almost completely prevented by knockdown or knockout of CREBH in Huh7.5.1 cells, suggesting that CREBH plays a critical role in profibrogenic responses induced by HCV infection.
In summary, we propose a model for induction of profibrogenic phenotypes triggered by HCV infection as follows (Fig. 7) . In HCV-infected hepatocytes, ER stress induced by viral infection can be a trigger for activation of CREBH. It is known that HCV infection also contributes to induction of ROS, possibly leading to phosphorylation of ATF2. (4) Activated CREBH (CREBH-N) and ATF2 recognize CRE-L and CREBHRE within the TGF-b2 promoter, resulting in transcriptional activation of TGF-b2 (Fig. 7A) . TGF-b2 that is released from infected cells contributes to cross-induction of total TGF-b in an autocrine manner through its own signaling pathway, finally leading to increased hepatic fibrogenic responses in HSCs adjacent to infected cells through paracrine TGF-b signaling (Fig. 7B) . In liver tissues, TGF-b isoforms are expressed not only in hepatocytes and HSC, but also Kupffer cells. To assess the cellular distribution of TGF-b2 transcript in the liver and its celltype-dependent change induced by HCV protein expression, cell fractions enriched either with hepatocytes, HSCs, or Kupffer cells were prepared from mouse livers with or without transient expression of HCV Core-NS2. Basal expression level of TGF-b2 in Kupffer cells was highest among cells tested; however, considering their cell numbers present in liver tissues, it appears that total amount of TGF-b2 expressed in the hepatocyte population is approximately 2-fold more abundant compared to that in the Kupffer cell population. In addition, up-regulation of TGF-b2 expression triggered by HCV protein expression was most markedly observed in hepatocytes, suggesting the critical role of hepatocytes in HCV-induced up-regulation of TGF-b2 expression (Supporting Fig. S13 ). Nevertheless, possible involvement of Kupffer cells in profibrogenic response triggered by HCV infection cannot be excluded. To further understand the detailed mechanisms controlling profibrogenic phenotypes induced by HCV infection, it would be desired to improve our co-culture system by introducing the Kupffer cell population.
